Marker Therapeutics
MRKR
65 hedge funds and large institutions have $44.5M invested in Marker Therapeutics in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 18 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.37% less ownership
Funds ownership: 3.75% → 3.38% (-0.37%)
11% less funds holding
Funds holding: 73 → 65 (-8)
23% less call options, than puts
Call options by funds: $160K | Put options by funds: $208K
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
49% less capital invested
Capital invested by funds: $87.6M → $44.5M (-$43.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$609K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$539K |
| 3 |
Renaissance Technologies
New York
|
+$433K |
| 4 |
BlackRock
New York
|
+$335K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$10.2M |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$511K |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
-$465K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$448K |
| 5 |
QCMA
Quad Capital Management Advisors
New York
|
-$298K |
MRKR Hedge Fund Activity: Q4 2019 in Review
65 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2019, worth a combined $44.5M — down 49% from $87.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of MRKR and 10 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 22 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $609K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.2M sold.
- 65 institutional investors held Marker Therapeutics (MRKR) as of Q4 2019, down from 73 in Q3 2019.
- Funds reported $44.5M of Marker Therapeutics stock for Q4 2019, down 49% quarter-over-quarter.
- 10 funds opened new Marker Therapeutics positions in Q4 2019 and 18 closed out, a net change of -8 holders.
- The largest Marker Therapeutics buyer in Q4 2019 was GSA Capital Partners, an estimated $609K added.
- The largest Marker Therapeutics seller in Q4 2019 was Perceptive Advisors, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2019.